The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO 2019 | CheckMate 459: updates on nivolumab monotherapy for HCC

Name: CheckMate 459: updates on nivolumab monotherapy for HCC
Uploaded: 2019-09-27T00:00:00Z
Duration: 3 min 46 s
Description: Thomas Yau, MD, Queen Mary Hospital, Hong Kong, China, gives an update on the CheckMate 459 trial (NCT02576509) results. This Phase III trial studies the use of nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. This interview was recorded at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Thomas Yau • 27 Sep 2019

ESMO 2019

Gastrointestinal Cancer Liver Cancer Nivolumab Sorafenib

CheckMate 459

Thomas Yau, MD, Queen Mary Hospital, Hong Kong, China, gives an update on the CheckMate 459 trial (NCT02576509) results. This Phase III trial studies the use of nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. This interview was recorded at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.